A Novel Therapeutic Approach for High-Risk and Relapsed/Refractory Neuroblastoma: Dinutuximab Beta
| Author | Elif Habibe Aktekin | en |
| Author | Nalan Yazıcı | en |
| Author | Ayşe Erbay | en |
| Author | Murat Ozkale | en |
| Orcid | Elif Habibe Aktekin [0000-0002-0394-6219] | en |
| Orcid | Nalan Yazıcı [0000-0003-4465-8229] | en |
| Orcid | Ayşe Erbay [0000-0001-7292-3822] | en |
| Orcid | Murat Ozkale [0000-0003-0625-1057] | en |
| Accessioned Date | 2026-06-16T06:47:15Z | |
| Issued Date | 2026-02-28 | en |
| Abstract | Background: Survival of patients in the high-risk group and those with relapsed/refractory neuroblastoma is significantly low. For these patients, results obtained with dinutuximab beta are promising. Objectives: In this study, we retrospectively analyzed our experience with dinutuximab beta in high-risk and relapsed/refractory neuroblastoma. Methods: Dinutuximab beta was given alternating with 13-cis retinoic acid as a component of maintenance therapy for high-risk group patients, and with 13-cis retinoic acid or a chemotherapy regimen for relapsed patients, with a continuous infusion at a dose of 10 mg/m2/day for 10 days. Adverse effect profiles and outcomes of patients were also examined. Results: Between March 2021-February 2023, 6 patients were treated for high-risk disease and 2 for relapsed disease with dinutuximab beta. Of all patients, seven are alive. One patient died due to severe capillary leak syndrome. The most common adverse effects during dinutuximab beta administration were fever, pain, and tachycardia, respectively. All adverse effects were managed without serious problems, except for the patient who had severe capillary leak. Pupil paralysis occurred as an unusual adverse effect. Conclusions: As a result of this study, dinutuximab beta can be an effective and reliable option in addition to standard treatment for patients diagnosed with high-risk and relapsed/refractory neuroblastoma compared with previous experience. However, especially in cases with pulmonary problems such as bronchopulmonary dysplasia, this drug should be carefully reassessed because of the irreversible adverse effect of capillary leak syndrome. | en |
| DOI | https://doi.org/10.5812/ijpediatr-160884 | en |
| URI | https://repository.brieflands.com/handle/123456789/67723 | |
| Keyword | Neuroblastoma | en |
| Keyword | Anti-GD2 | en |
| Keyword | Dinutuximab Beta | en |
| Keyword | High-Risk Group | en |
| Keyword | Relapsed Disease | en |
| Publisher | Brieflands | en |
| Title | A Novel Therapeutic Approach for High-Risk and Relapsed/Refractory Neuroblastoma: Dinutuximab Beta | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijp-36-1-160884-publish-pdf.pdf
- Size:
- 712.13 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF